Update: Milestone Pharmaceuticals (MIST) - Building the Foundation for Launch (and Deals)
Milestone appoints a new General Counsel just days before the sales force hits the streets. Here is why his resume matters for the thesis.
The News: Bringing in the Heavyweight
On February 10, 2026, Milestone Pharmaceuticals announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer.
He joins the executive leadership team right as CARDAMYST (etripamil) nasal spray rolls out as the first approved self-administered treatment for adult PSVT patients.
